How it works: NAB PACLITERO disrupts cancer cell division by stabilising microtubules, halting mitosis and triggering cell death. The nanoparticle formulation enhances tumour targeting and reduces systemic toxicity.
Who it’s for:
– Patients with metastatic or localised breast cancer
– Those with non-small cell lung cancer, in combination with carboplatin
– Individuals with pancreatic cancer, together with gemcitabine
– Patients seeking an effective, safer alternative to conventional paclitaxel
– Metastatic breast cancer
– Non-small cell lung cancer
– Pancreatic cancer (with gemcitabine)
The drug is administered via intravenous infusion after reconstitution according to protocol. Dosage and schedule depend on cancer type, stage, and treatment regimen. Use is strictly under physician supervision in hospital or oncology clinic.
Contraindicated in patients allergic to paclitaxel or albumin, in severe neutropenia, during pregnancy or breastfeeding.
Possible side effects include bone marrow suppression, peripheral neuropathy, nausea, alopecia, and fever. Regular blood monitoring and supervision are essential.
